orforglipron semaglutide comparison Orforglipron: The Oral Non-Peptide GLP-1 Agonist Orforglipron FDA Approved April 2026:

Cardiovascular outcome trials in patients with T2D have demonstrated the efficacy of GLP-1 RAs in reducing major adverse cardiovascular events, including cardiovascular death, MI and stroke, regardless of glycaemic control

My Takeaway Thus Far At the end of the day, what matters most to me is seeing people win the fight against addiction

This is especially true for people taking diabetes medications

Start low: Begin around 250 g daily for 12 weeks Increase gradually: Up to 500 g twice daily if tolerated Cycle: 46 weeks on, then take 24 weeks off This approach supports tendon, muscle, or ligament healing without overloading the system